In this interview with Dr Robert Ryder (Sandwell and West Birmingham NHS Trust, City Hospital, Birmingham, UK), he explains how the EndoBarrier device works and how it aids weight loss and glycemic control in patients with diabetes. Those who would benefit from this device typically have a long duration of diabetes, are obese, and are poorly controlled despite interventions and lifestyle changes. Dr Ryder reviews the outcomes of patients who have had an EndoBarrier, which include reductions in weight, body mass index, glycated hemoglobin, and insulin usage. He also noted improvements in alanine transaminase and blood pressure. A frequent comorbidity of obese patients with diabetes is obstructive sleep apnea. Dr Ryder explains how EndoBarrier-induced weight loss contributed to a reduction in the risk of sleep apnea to the point where patients no longer required continuous positive airway pressure.
1. What is the EndoBarrier and how does it work? (0:13)
2. Which patients are suitable for the EndoBarrier? (1:12)
3. Can you describe the UK’s 1st NHS EndoBarrier service , and the outcomes you presented at this meeting? (1:54)
4. What were the key findings of the study you presented at this meeting around EndoBarrier in patients with type 2 diabetes or prediabetes and obstructive sleep apnoea ? (3:28)
Filmed at the American Diabetes Association (ADA) Annual Meeting, June 2018